• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
  • Contact
  • About
Thursday, June 30, 2022
Maryland Digital News
  • Home
  • US
  • Business
  • World
  • Baltimore
  • Columbia
  • Germantown
  • Waldorf
  • Silver Spring
  • Frederick
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Baltimore
  • Columbia
  • Germantown
  • Waldorf
  • Silver Spring
  • Frederick
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Silver Spring

FDA Takes Actions To Expand Use Of Treatment For Outpatients With Mild-To-Moderate COVID-19

by NewsReporter
January 21, 2022
in Silver Spring
Reading Time: 6 mins read
fda-takes-actions-to-expand-use-of-treatment-for-outpatients-with-mild-to-moderate-covid-19
Share on FacebookShare on Twitter

PR Newswire

SILVER SPRING, Md., Jan. 21, 2022

SILVER SPRING, Md., Jan. 21, 2022 /PRNewswire/ — Today, the U.S. Food and Drug Administration took two actions to expand the use of the antiviral drug Veklury (remdesivir) to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. This provides another treatment option to reduce the risk of hospitalization in high-risk patients. Previously, the use of Veklury was limited to patients requiring hospitalization.

“On the heels of the FDA’s recent authorization of two oral antiviral drugs, today’s actions bolster the arsenal of therapeutics to treat COVID-19 and respond to the surge of the omicron variant,” said Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research. “Today’s actions provide adults and pediatric patients, with mild-to-moderate COVID-19 who are at high risk of severe COVID-19, with a treatment option they could receive outside of a traditional inpatient hospital setting, including at skilled nursing facilities, home healthcare settings and outpatient facilities such as infusion centers.”

Veklury is not a substitute for vaccination in individuals for whom COVID-19 vaccination and a booster dose are recommended. The FDA has approved one vaccine and authorized others to prevent COVID-19 and the serious clinical outcomes associated with COVID-19, including hospitalization and death. The FDA urges the public to get vaccinated and receive a booster if eligible. Learn more about FDA-approved or -authorized COVID-19 vaccines.

The FDA has expanded the approved indication for Veklury to include its use in adults and pediatric patients (12 years of age and older who weigh at least 40 kilograms, which is about 88 pounds) with positive results of direct SARS-CoV-2 viral testing, and who are not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

The agency also revised the Emergency Use Authorization (EUA) for Veklury to additionally authorize the drug for treatment of pediatric patients weighing 3.5 kilograms to less than 40 kilograms or pediatric patients less than 12 years of age weighing at least 3.5 kilograms, with positive results of direct SARS-CoV-2 viral testing, and who are not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization of death.

Based on today’s actions, these high-risk non-hospitalized patients may receive Veklury via intravenous infusion for a total of three days for the treatment of mild-to-moderate COVID-19 disease.

The approval of Veklury for use in non-hospitalized patients is supported by a randomized, placebo-controlled clinical trial that included 562 non-hospitalized patients with mild-to-moderate COVID-19 who were at high risk for progression to severe COVID-19, including hospitalization or death. The main outcome measured in the trial was whether a patient was hospitalized for any COVID-19 related reason or died from any reason within 28 days of treatment. Overall, 2 of 279 patients who received Veklury (0.7%) required COVID-19 related hospitalization compared to 15 of 283 patients who received a placebo (5.3%). There were no deaths in either group.

Pediatric patients for whom Veklury is authorized will receive doses adjusted for their body weight in order to achieve comparable exposures to adults and pediatric patients receiving the approved dose. Given the similar course of COVID-19 disease, the authorization of Veklury in certain pediatric patients is based on extrapolation of efficacy from adequate and well-controlled studies in adults.

Important details about using Veklury to treat COVID-19 for its approved use is available in the prescribing information, which includes dosing instructions, potential side effects and drug interactions. Possible side effects include increased levels of liver enzymes, which may be a sign of liver injury; and allergic reactions, which may include changes in blood pressure and heart rate, low blood oxygen level, fever, shortness of breath, wheezing, swelling (e.g., lips, around eyes, under the skin), rash, nausea, sweating or shivering. Similar safety information about using Veklury to treat COVID-19 in certain non-hospitalized pediatric patients under the EUA is available in the fact sheets for health care providers and parents/caregivers.

The FDA granted approval and reissued the revised EUA to Gilead Sciences Inc.

Additional Resources:

  • Remdesivir EUA Letter of Authorization

  • Frequently Asked Questions for Veklury (remdesivir)

  • Emergency Use Authorization: Drugs and Non-Vaccine Biological Products

  • Coronavirus Treatment Acceleration Program (CTAP)

  • Coronavirus Disease (COVID-19)

  • National Institutes of Health COVID-19 Treatment Guidelines for High-Risk, Non-hospitalized Patients with Mild to Moderate COVID-19

# # #

Media Contact: Chanapa Tantibanchachai, 202-384-2219

Consumer Inquiries: Email or 888-INFO-FDA (888-463-0332)

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-takes-actions-to-expand-use-of-treatment-for-outpatients-with-mild-to-moderate-covid-19-301466070.html

SOURCE U.S. Food and Drug Administration

Read More Here

Related Posts

5-things-to-know-today,-april-14,-in-montgomery-county

5 Things To Know Today, April 14, In Montgomery County

by NewsReporter
April 14, 2022
0

It’s Thursday, April 14 and here are five things to know in Montgomery County. 1. State of the County: Montgomery County Executive Marc Elrich will deliver his 2022 “State of the County” address at noon at the Silver Spring Civic Building. This will be County Executive Elrich’s first in-person State...

senator-demands-answers-from-fda

Senator Demands Answers From FDA

by NewsReporter
April 13, 2022
0

U.S. Sen. Patty Murray (D-WA), Chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, sent a letter to Food and Drug Administration (FDA) Commissioner Robert M. Califf urging answers and immediate action following a Politico report that lays bare a culture of delay and inaction in the agency’s...

what-le-pen-would-(and-wouldn’t)-do-if-she-beats-macron

What Le Pen Would (And Wouldn’t) Do If She Beats Macron

by NewsReporter
April 12, 2022
0

FRENCH TWIST — If Marine Le Pen becomes the next president of France, the European Union won’t collapse. Neither will the euro. There isn’t going to be a Frexit.But the far-right politician is a genuine threat to the liberal Western order. Here’s why you should worry she could win France’s...

ville-valo,-ex-him-lead-singer-announces-2023-us-tour

Ville Valo, Ex-HIM Lead Singer Announces 2023 US Tour

by NewsReporter
April 11, 2022
0

(CelebrityAccess) – Former HIM frontman Ville Valo (VV) has announced a 2023 tour of the United States supporting his album Neon Noir. The Finnish singer/songwriter has confirmed his next album will be released in early 2023. In addition to the announced US dates, VV will also be hitting Europe and...

Maryland Digital News

© 2021 Maryland Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
  • Contact
  • About

Follow Us

No Result
View All Result
  • Home
  • About
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Maryland Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT